Biogen (BIIB) Land & Improvements (2009 - 2010)
Biogen (BIIB) recorded quarterly Land & Improvements of $107.6 million in Q4 2010, down 3.24% quarter-over-quarter from $111.2 million in Q4 2009, and down 3.24% on a YoY basis from $111.2 million in Q4 2009.
Biogen (BIIB) Land & Improvements (2009 - 2010) Analysis & Trends
Biogen's Land & Improvements history runs 2 years deep, the most recent figure standing at $107.6 million for Q4 2010.
- In Q4 2010, Land & Improvements fell 3.24% year-over-year to $107.6 million; the TTM figure through Dec 2010 stood at $107.6 million (down 3.24% YoY), while the FY2010 annual figure was $107.6 million, down 3.24% from the prior year.
- Land & Improvements was $107.6 million for Q4 2010 at Biogen, down from $111.2 million in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $111.2 million in Q4 2009 to a low of $107.6 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 157.00 Mn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 107.60 Mn |
| Dec 31, 2009 | 111.20 Mn |